News

Study finds why immunotherapies don’t work on hardest-to-treat breast cancers

Keith Brannon
By Keith Brannon
Feb. 4, 2023

Thanks to advances in cancer therapies, most forms of breast cancer are highly treatable, especially when caught early.

But the last frontier cases — those that can’t be treated with hormone or targeted therapies and don’t respond to chemotherapy — remain the deadliest and hardest to treat. Tulane University researchers have discovered for the first time how these cancers persist after chemo and why they don’t respond well to immunotherapies designed to clear out remaining tumor cells by revving up the immune system. 

The process of surviving chemotherapy triggers a program of immune checkpoints that shield breast cancer cells from different lines of attack by the immune system.
The process of surviving chemotherapy triggers a program of immune checkpoints that shield breast cancer cells from different lines of attack by the immune system.

The process of surviving chemotherapy triggers a program of immune checkpoints that shield breast cancer cells from different lines of attack by the immune system. It creates a “whack-a-mole” problem for immunotherapy drugs called checkpoint inhibitors that may kill tumor cells expressing one checkpoint but not others that have multiple checkpoints, according to a new study published in the journal Nature Cancer.

“Breast cancers don't respond well to immune checkpoint inhibitors, but it has never really been understood why,” said corresponding author James Jackson, associate professor of biochemistry and molecular biology at Tulane University School of Medicine. “We found that they avoid immune clearance by expressing a complex, redundant program of checkpoint genes and immune modulatory genes. The tumor completely changes after chemotherapy treatment into this thing that is essentially built to block the immune system.”

Researchers studied the process in mouse and human breast tumors and identified 16 immune checkpoint genes that encode proteins designed to inactivate cancer-killing T-cells. 

“We’re among the first to actually study the tumor that survives post-chemotherapy, which is called the residual disease, to see what kind of immunotherapy targets are expressed,” said the study’s first author Ashkan Shahbandi, an M.D./Ph.D. student in Jackson's lab. 

The tumors that respond the worst to chemotherapy enter a state of dormancy — called cellular senescence — instead of dying after treatment. Researchers found two major populations of senescent tumor cells, each expressing different immune checkpoints activated by specific signaling pathways. They showed the expression of immune evasion programs in tumor cells required both chemotherapy to induce a senescent state and signals from non-tumor cells.  

They tested a combination of drugs aimed at these different immune checkpoints. While response could be improved, these strategies failed to fully eradicate the majority of tumors.

“Our findings reveal the challenge of eliminating residual disease populated by senescent cells that activate complex immune inhibitory programs,” Jackson said. “Breast cancer patients will need rational, personalized strategies that target the specific checkpoints induced by the chemotherapy treatment.”

This article first appeared in Tulane News. Read the original.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Keith Brannon
Keith Brannon

Keith Brannon is director of public relations and media at Tulane University.

Related articles

Seeking leukemia’s Achilles heel
Marissa Locke Rottinghaus
From the journals: March 2019
John Arnst, Courtney Chandler, Isha Dey & Catherine Goodman
From the journals: March 2018
Sasha Mushegian, Laurel Oldach & Saddiq Zahari

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Where the heck did all those structures inside complex cells come from?
Feature

Where the heck did all those structures inside complex cells come from?

Dec. 3, 2023

Scientists agree that eons ago, a bacterium took up residence inside another cell and became its powerhouse, the mitochondrion. But there are competing theories about the birth of other organelles such as the nucleus and endoplasmic reticulum.

Untangling the genetics that underlie our facial features
Feature

Untangling the genetics that underlie our facial features

Dec. 2, 2023

After turning up hundreds of genes with hard-to-predict effects, some scientists are now probing the grander developmental processes that shape face geometry.

From the journals: JLR
Journal News

From the journals: JLR

Dec. 1, 2023

A safer combination therapy for liver disease. A mechanistic pathway of the pathophysiology of NASH. A novel therapeutic target for heart failure. Read about recent papers on these topics.

Insulin injections could one day be replaced with rock music
News

Insulin injections could one day be replaced with rock music

Nov. 26, 2023

Using mice, researchers engineered cells to release insulin in response to specific sound waves: the music of the band Queen.

From the journals: JBC
Journal News

From the journals: JBC

Nov. 24, 2023

Protein cleavage in polycystic kidney disease. Expanding tools to study ion channels. Mechanisms of 5-fluorouracil cytotoxicity and chemoresistance. Read about papers on these topics.

Detecting biomarkers for deadly lung disease
Journal News

Detecting biomarkers for deadly lung disease

Nov. 21, 2023

A group led by scientists from Genentech Inc is studying whether bioactive lipid species can predict idiopathic pulmonary fibrosis progression.